Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2023-10-18 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
关于持股5%以上股东股份减持计划届满的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the completion of a shareholding reduction plan by a shareholder holding more than 5% of the company's shares. It details the reduction in shares, the compliance with relevant laws and regulations, and the impact on the company's shareholding structure. There are no financial statements or detailed financial performance data. The document is focused on shareholding changes by a major shareholder, specifically the reduction of shares held. This fits the definition of a Major Shareholding Notification (MRQ). The document length is short and it is not a report or a certification, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA). Therefore, the correct classification is MRQ with high confidence.
2023-10-18 Chinese
2023年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 2023 third extraordinary shareholders' meeting of Sailong Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, voting results on proposals, and legal opinions confirming the validity of the meeting and voting process. There is no detailed financial data or comprehensive report content; rather, it is a summary of voting outcomes and meeting procedures. This fits the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA). The document length is short (1951 characters), and it is not a report publication announcement or a full report. Therefore, the correct classification is DVA with high confidence.
2023-10-09 Chinese
关于赛隆药业集团股份有限公司2023年第三次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and procedural compliance of the company's 2023 third extraordinary shareholders' meeting. It details the convening, attendance, voting procedures, and results of the shareholders' meeting. It does not contain financial statements or management discussion but focuses on the legal validation of the shareholders' meeting process and voting outcomes. The document is not a report itself but a legal opinion related to a shareholders' meeting. This type of document fits best under Regulatory Filings (RNS) as it is a compliance/legal procedural filing rather than a financial report or announcement of voting results.
2023-10-09 Chinese
关于变更信息披露媒体的公告
Regulatory Filings Classification · 100% confidence The document is a short announcement regarding the change of designated information disclosure media by the company. It does not contain financial data, management changes, voting results, or any detailed report content. It is a regulatory announcement about disclosure practices, not a report or detailed filing. The document length is only 444 characters, indicating it is a brief notice. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2023-09-12 Chinese
半年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings
2023-08-24 Chinese
监事会关于公司计提及转回减值准备事项合理性的说明
Regulatory Filings Classification · 95% confidence The document is a statement from the supervisory board (监事会) of a company regarding the reasonableness of impairment provisions and reversals for the half-year period of 2023. It references compliance with accounting standards and stock exchange listing rules, and confirms the appropriateness of the accounting treatment and decision procedures. The document is very short (412 characters) and serves as an explanatory note or confirmation rather than a full financial report or audit report. It does not contain detailed financial data or comprehensive analysis. It is not an announcement of voting results, management changes, or legal proceedings. Given the nature and length, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-08-24 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.